comparemela.com

Latest Breaking News On - New therapies - Page 7 : comparemela.com

TISSIUM Appoints Sara Toyloy as Independent Board Member

TISSIUM Appoints Sara Toyloy as Independent Board Member
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
California
Paris
France-general
France
Romain-attard
Sara-toyloy
Yoann-besse
Jeffreym-karp-brigham
Christophe-bancel

WissenHoch2 in 3sat über neue Therapien gegen Parkinson und Alzheimer / Mit einer Wissenschaftsdoku und einer Ausgabe von scobel

Mainz (ots) - Donnerstag, 22. September 2022, ab 20.15 UhrErstausstrahlungenDie Parkinson-Krankheit betrifft Millionen Menschen weltweit. Einige Symptome lassen sich mit Medikamenten lindern, doch eine

Germany
Copenhagen
Køavn
Denmark
German
Leader-of-working-group
University-hospital
Drug-research
University-copenhagen
Scobel-the-program
University-hospital-schleswig-holstein

Merus N.V.: Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific

Cambridge
Cambridgeshire
United-kingdom
Netherlands
Exchange-commission
Nasdaq
Molecular-targets
New-therapies
Private-securities-litigation-reform-act
Quarterly-report
Emerus

Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics

07.09.2022 - UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies . Seite 1

New-therapies

Merus Announces Poster Presentation on MCLA-129 at the 34th

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a.

Cambridge
Cambridgeshire
United-kingdom
Netherlands
Exchange-commission
Molecular-targets
New-therapies
Private-securities-litigation-reform-act
Quarterly-report
Nasdaq-mrus
Merusnv

vimarsana © 2020. All Rights Reserved.